Enfusion Statistics
Total Valuation
Enfusion has a market cap or net worth of $1.37 billion. The enterprise value is $1.34 billion.
| Market Cap | 1.37B |
| Enterprise Value | 1.34B |
Important Dates
The last earnings date was Monday, November 4, 2024, before market open.
| Earnings Date | Nov 4, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Enfusion has 128.57 million shares outstanding. The number of shares has increased by 7.71% in one year.
| Current Share Class | 94.37M |
| Shares Outstanding | 128.57M |
| Shares Change (YoY) | +7.71% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 10.73% |
| Owned by Institutions (%) | 51.35% |
| Float | 37.80M |
Valuation Ratios
The trailing PE ratio is 500.99 and the forward PE ratio is 39.68.
| PE Ratio | 500.99 |
| Forward PE | 39.68 |
| PS Ratio | 4.93 |
| Forward PS | 5.83 |
| PB Ratio | 14.18 |
| P/TBV Ratio | 19.55 |
| P/FCF Ratio | 49.44 |
| P/OCF Ratio | 43.26 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 72.30, with an EV/FCF ratio of 48.45.
| EV / Earnings | 491.03 |
| EV / Sales | 6.86 |
| EV / EBITDA | 72.30 |
| EV / EBIT | 119.55 |
| EV / FCF | 48.45 |
Financial Position
The company has a current ratio of 3.62, with a Debt / Equity ratio of 0.22.
| Current Ratio | 3.62 |
| Quick Ratio | 3.41 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 0.76 |
| Debt / FCF | 0.76 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 5.48% and return on invested capital (ROIC) is 6.76%.
| Return on Equity (ROE) | 5.48% |
| Return on Assets (ROA) | 5.92% |
| Return on Capital (ROIC) | 6.76% |
| Revenue Per Employee | $177,095 |
| Profits Per Employee | $2,475 |
| Employee Count | 1,102 |
| Asset Turnover | 1.65 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Enfusion has paid $2.47 million in taxes.
| Income Tax | 2.47M |
| Effective Tax Rate | 34.71% |
Stock Price Statistics
The stock price has increased by +6.73% in the last 52 weeks. The beta is 0.98, so Enfusion's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +6.73% |
| 50-Day Moving Average | 9.68 |
| 200-Day Moving Average | 9.11 |
| Relative Strength Index (RSI) | 59.58 |
| Average Volume (20 Days) | 475,132 |
Short Selling Information
The latest short interest is 820,410, so 0.64% of the outstanding shares have been sold short.
| Short Interest | 820,410 |
| Short Previous Month | 1.18M |
| Short % of Shares Out | 0.64% |
| Short % of Float | 2.17% |
| Short Ratio (days to cover) | 1.55 |
Income Statement
In the last 12 months, Enfusion had revenue of $195.16 million and earned $2.73 million in profits. Earnings per share was $0.03.
| Revenue | 195.16M |
| Gross Profit | 131.06M |
| Operating Income | 11.21M |
| Pretax Income | 5.67M |
| Net Income | 2.73M |
| EBITDA | 18.53M |
| EBIT | 11.21M |
| Earnings Per Share (EPS) | $0.03 |
Balance Sheet
The company has $48.30 million in cash and $21.13 million in debt, giving a net cash position of $27.17 million or $0.21 per share.
| Cash & Cash Equivalents | 48.30M |
| Total Debt | 21.13M |
| Net Cash | 27.17M |
| Net Cash Per Share | $0.21 |
| Equity (Book Value) | 96.18M |
| Book Value Per Share | 0.75 |
| Working Capital | 61.87M |
Cash Flow
In the last 12 months, operating cash flow was $31.60 million and capital expenditures -$3.95 million, giving a free cash flow of $27.65 million.
| Operating Cash Flow | 31.60M |
| Capital Expenditures | -3.95M |
| Free Cash Flow | 27.65M |
| FCF Per Share | $0.22 |
Margins
Gross margin is 67.15%, with operating and profit margins of 5.74% and 1.70%.
| Gross Margin | 67.15% |
| Operating Margin | 5.74% |
| Pretax Margin | 3.64% |
| Profit Margin | 1.70% |
| EBITDA Margin | 9.49% |
| EBIT Margin | 5.74% |
| FCF Margin | 14.17% |
Dividends & Yields
Enfusion does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.71% |
| Shareholder Yield | -7.71% |
| Earnings Yield | 0.20% |
| FCF Yield | 2.02% |
Analyst Forecast
The average price target for Enfusion is $9.80, which is -7.81% lower than the current price. The consensus rating is "Hold".
| Price Target | $9.80 |
| Price Target Difference | -7.81% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Enfusion has an Altman Z-Score of 12.99 and a Piotroski F-Score of 5.
| Altman Z-Score | 12.99 |
| Piotroski F-Score | 5 |